Month: February 2023

No Chat offers a clever way to communicate on a phone screen APP

“Drake using No Chat”
There is a slick new iPhone app that I tried this weekend called No Chat. It allows you to get someone’s attention just by flashing your phone screen.

New app offers a clever way to communicate using your phone screen

There is a slick new iPhone app that I tried this weekend called No Chat. It allows you to get someone’s attention just by flashing your phone screen. Picture being in a loud bar or restaurant, and rather than yelling your drink order, you just hold up your phone. That is the idea of No Chat – to allow you to create a quick custom message displayed or flashed (aggressively, I might add) on your phone. It seems silly, but it works well. I used it today leaving work to hail a cab. I can see myself using this in a ton of other scenarios, like when I want to close my tab quickly at a restaurant or maybe even trolling a band to play a specific song.

Here’s how it works: https://www.youtube.com/watch?v=LDrrglPBolw

I reached out to the creator of the app after finding his videos on TikTok and was astonished that he filed to patent the idea and has a bunch of new features being added. “I started seeing a trend in bars and concerts where people took blank Snapchats to write a quick message on their screen to communicate with an artist, and thought there has to be a better way!” said Matt Hagens, creator of No Chat.

I can see just by using it for a few days that No Chat has an endless amount of uses – hailing a taxi, telling a Lyft or Uber where you are, communicating with an artist, bartender, or server, all with your own custom message flashed on your screen.

https://www.tiktok.com/@matthagens.com/video/7135274320955215147

It’s worth noting that No Chat has already gained popularity among some big names in the entertainment industry. Mark Cuban, Drake, and Diplo are just a few of the high-profile individuals who have utilized this innovative app.

Don’t yell – show your phone screen.

You can try No Chat for yourself here: https://hagensmedia.com/nochat/install/

Media Contact
Company Name: H.Media
Contact Person: Zo Bear
Email: Send Email
Country: United States
Website: https://hagensmedia.com/nochat

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: No Chat offers a clever way to communicate on a phone screen APP

Become an Elite-League Life Coach With Gabriela Embon and the Coaching Academy

“Business, Human Resources, Education, Lifestyle, Professional Services”
Equipping the Next Generation of Coaches With the Training and Resources Needed to Stand Out

MONTREAL, CA – For many people, life coaching is a dream career. It offers flexibility, work-life balance, and a sense of ownership. Most importantly, it allows people to experience the fulfillment that comes from pouring into other people and helping them grow. Today, coaching is one of the fastest-growing industries in the world, and there is a constant demand for new coaches to emerge. Everyday people are looking for top-tier life coaches to support them, develop them, and help them find satisfaction in all aspects of life. Despite this growing need, however, many professional coaches struggle to stand out among their competitors. This begs the question, what makes a coach irresistible, extraordinary, and successful? Gabriela Embon, founder of the Coaching Academy, is delivering the training and resources needed to transform aspiring coaches into elite-league coaches and business owners who stand out in their fields.

There are two elements that have the power to affect change in someone’s life—action and mindset. Coaches tend to emphasize the action component of this formula. While they may speak to the importance of mindset and beliefs systems, many fail to provide effective tools to help clients shift their limiting paradigms. Without this internal transformation, clients aren’t able to hold or embody the results that they are working towards. The truth is that, in order for a coach to become irresistible to clients, extraordinary in their field, and successful as a life coach, they need to address both levels. Ultimately, this is what separates an elite-league coach and a coach who merely blends in.

Now, through the Coaching Academy’s flagship product, the Life Coaching Certification program, coaches can learn this methodology and guide their clients to bring about real, lasting change. Much of the course focuses on the concept of rewiring the brain, which incorporates elements of coaching, entrepreneurship, and healing. By learning this concept and implementing it into their own coaching programs, coaches are able to help their clients embark on their own personal transformation journeys—identifying the results they want, fostering the right mindset, and then taking the necessary steps to achieve those results. To date, The Coaching Academy has graduated more than 1,000 students, many of whom have gone on to build some of the most successful and impactful coaching businesses in their respective industries.

The next Life Coaching Certification program launches April 27th, 2023. To enroll in the program, click here. For more information about Gabriela and the Coaching Academy, visit the company’s website.

Media Contact
Company Name: Coaching Academy by Gabriela Embon
Contact Person: Gabriela Embon
Email: Send Email
Phone: +1 514 690 6000
City: Montreal
State: Quebec
Country: Canada
Website: coachingacademy.net

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Become an Elite-League Life Coach With Gabriela Embon and the Coaching Academy

Entertainment Spotlight: Niki J. Borger – Actress, Screenwriter, Producer

Niki J. Borger is a multi-award winning actress, screenwriter and producer who grew up on the German countryside and is fluent in English, French, Spanish and German. She moved to the US in September of 2018 to pursue her passion of a career in the Hollywood entertainment industry. 

“As a cosmopolitan, I believe that we live in one world and that every living being has a unique purpose within it. Through my work and how I live, I want to inspire others, I want to show that so much more is possible than some might think. For Everybody.” – Niki J. Borger 

She is the co-founder of FireWolf Entertainment, a production company based in Oklahoma and Burbank, California. FireWolf Entertainment specializes in telling compelling stories in the fantasy and action genre, similar to Game of Thrones or the Marvel Cinematic Universe. The company is different in that they produce characters and story arcs that are a lot more authentic and relatable than most other films in the genre, as well as going deeper into the psychology, mindsets, beliefs, and driving factors of the characters to see what makes them human (or not). The storylines they work with at FireWolf Entertainment might be hard and dark along the way, but lead to uplifting and inspiring outcomes. 

Her short “Because I Could” that she wrote, directed, produced and acted in was nominated and won several awards around the world.  “Because I Could” is a short film that is set twenty years in the future, where four adults confess their day-to-day climate sins and why they didn’t do things any better. 

She also wrote and starred in in the award-winning short “A Portrayal Of A Subtle Suicide” directed by Matt Macedo and hosts the personal breakthrough show “Unlimit Yourself.” “Unlimit Yourself” is a weekly show of personal development. With the help of experts and guests, the show aims at inspiring viewers to create positive changes in their lives. 

Niki J. Borger is taking the entertainment world by storm, and we look forward to watching her rise through the Hollywood ranks. 

Social Media:

Facebook Page: https://www.facebook.com/profile.php?id=100069070134064

Instagram Profile: https://www.instagram.com/nikijborger/

Youtube: https://www.youtube.com/channel/UCO8kBxwCdcLCjttdZi3X12A

Webpage: https://nikijborger.com/

FireWolf Entertainment: https://firewolfent.com/

Media Contact
Company Name: World Star PR
Contact Person: Jimmy Star
Email: Send Email
Phone: 631-506-6600
Country: United States
Website: https://www.facebook.com/WorldStarPR/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Entertainment Spotlight: Niki J. Borger – Actress, Screenwriter, Producer

New Institution Joins The Ranks Of e-Local Marketplace B2B Buyers

Calling All Corporations and Institutions to Support Chicagoland Small Businesses

e-Local Marketplace (“ELM”), is the “go to” marketplace for corporations and institutions seeking to dedicate a portion of annual spending among Chicagoland small businesses. “Evanston/Skokie School District #65 made the announcement to their end users; and they can start buying now.” stated Cy Kennedy, CEO of Value Innovation Technologies, the tech company that powers e-Local Marketplace. “The City of Evanston has also executed their commitment to join as an ELM Buyer. We anticipate their rollout of e-Local Marketplace to all City of Evanston departments in the very near future.” shared Clarence Weaver, ELM President. These institutions are among a growing number of ELM Buyers, Northwestern University was the first to sign in Evanston. 

Hotels, medical, university procurement officers and corporate leaders wanting to make a difference in the communities in which they are located; among the people, patients and students they serve, would be remiss to not at least consider e-Local Marketplace. “According to Q4 ‘22 data, the city of Chicago alone serves as the headquarters to 35 Fortune 500 companies. It is also the location of a couple of the US News & World Report’s ’50 Best Hotels’ List for 2023, some of the most tremendous higher institutions of learning, greatest hospitals, and home to McCormick Place, the largest exhibition center in North America.” stated Anita Summers, ELM Executive Director. She continued “e-Local Marketplace is excited to present authentic local options for the  procurement needs of all of these entities.” e-Local Marketplace (“ELM”), provides a direct solution to corporate and institutional buyers’ DEI initiatives and other entities committed to supporting local, women, minority, and veteran-owned businesses throughout the 9,581 square mile Chicagoland area. 

e-Local Marketplace Buyers have ongoing opportunities to advise ELM regarding the products they seek to purchase, customize [their] buyer catalogues, and have access to over 100 additional data points on B2B metrics. System integration is offered; however, it is not a requirement. Currently, buyers can select from over 100k products including unique coffees, food service, Maintenance Repair Operations (MRO), office supplies, graphic design, digital marketing, printing, artificial intelligence (AI), cyber security, and commercial interior design and overhead doors.

Corporate and institutional decision makers are invited to express interest or questions via email to asummers@e-localmarketplace.org or call (224) 357-1107 to schedule a meeting and/or system demonstration. Small business owners may email questions or register to become an e-Local Marketplace vendor at: https://evanstonlocalmarketplace.elinkgateway.com/administration/vendorRegform/vendorregpage.xhtml. 

ELM is powered by eLink Gateway™, a proprietary software of Value Innovation Technologies.

Media Contact
Company Name: E-Local Marketplace
Contact Person: Anita Summers
Email: Send Email
City: Chicago
Country: United States
Website: e-localmarketplace.org

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Institution Joins The Ranks Of e-Local Marketplace B2B Buyers

Niemann Pick Disease Marketed and Emerging Pipeline Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

“Delveinsight Business Research LLP”
As per DelveInsight’s assessment, about 20+ key pharma and biotech companies are working on 20+ pipeline drugs in the Niemann Pick Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Niemann Pick Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Niemann Pick Disease Market. 

The Niemann Pick Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Niemann Pick Disease Pipeline Analysis

Niemann Pick Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Niemann Pick Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Niemann Pick Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 

Route of Administration

Niemann-Pick-Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

 

Molecule Type

The emerging products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule

 

Learn How the Ongoing Clinical & Commercial Activities will Affect the Niemann Pick Disease Therapeutic Segment @

https://www.delveinsight.com/sample-request/niemann-pick-disease-pipeline-insight

Niemann Pick Disease Therapeutics Landscape

There are approx. 20+ key companies developing therapies for Niemann-Pick-Disease. Currently, Orphazyme is leading the therapeutics market with its Niemann-Pick-Disease drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Niemann Pick Disease Therapeutics Market Include:

  • Orphazyme

  • Cyclo Therapeutics

  • Mandos LLC

  • IntraBio

  • E-scape Bio

  • Scenic Biotech

  • Synaptogenix

  • Evox Therapeutics

  • StrideBio

  • SOM Biotech

  • ENDECE

  • Oraxion Therapeutics

  • Polaryx Therapeutics

And Many More

Niemann-Pick-Disease Drugs Covered in the Report Include

  • Arimoclomol: Orphazyme

  • Trappsol Cyclo: Cyclo Therapeutics

  • VTS-270: Mandos LLC

  • ESB1609: E-scape Bio

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/niemann-pick-disease-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Niemann Pick Disease Current Treatment Patterns

4. Niemann Pick Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Niemann Pick Disease Late Stage Products (Phase-III)

7. Niemann Pick Disease Mid-Stage Products (Phase-II)

8. Niemann Pick Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Niemann Pick Disease Discontinued Products

13. Niemann Pick Disease Product Profiles

14. Key Companies in the Niemann Pick Disease Market

15. Key Products in the Niemann Pick Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Niemann Pick Disease Unmet Needs

18. Niemann Pick Disease Future Perspectives

19. Niemann Pick Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/niemann-pick-disease-pipeline-insight

 

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Niemann Pick Disease Marketed and Emerging Pipeline Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Insights, 2023 Updates | Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

As per DelveInsight’s assessment, globally, about 120+ key pharma and biotech companies are working on 460+ pipeline drugs in the Chimeric Antigen Receptor (CAR) T-Cell Therapy landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Insight, 2023″ report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  CAR T-cell Therapy Market. 

The CAR T-cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Analysis

Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging CAR T-cell Therapy in the Market and the aggregate therapies developed by major pharma companies.

  • It accesses the different CAR T-cell Therapy therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the CAR T-cell Therapy Market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 

Route of Administration

CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Intravenous

  • Intramuscular

  • Subcutaneous

  • Intratumoral

 

Mechanism of Action

Products have been categorized under various Mechanisms of Action, such as

  • T lymphocyte replacements

  • Immunologic cytotoxicity

 

Learn How the Ongoing Clinical & Commercial Activities will Affect the CAR T-cell Therapy Therapeutic Segment @ 

https://www.delveinsight.com/sample-request/cart-cell-therapy-competitive-landscape

Chimeric Antigen Receptor (CAR) T-Cell TherapyTherapeutics Landscape

There are approx. 120+ key companies which are developing Chimeric Antigen Receptor (CAR) T-Cell Therapy. Currently, JW Therapeutics is leading the therapeutics market with its CAR-T drug candidates in the most advanced stage of clinical development.

The Leading Players in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Include:

AbbVie, AbCLon, Actinium Pharmaceuticals, Adagene, Adicet Bio, AffyImmune Therapeutics, AgenTus Therapeutics, Allife Medical Science and Technology, Allogene Therapeutics, Amgen/Kite Pharma, Anixa Biosciences, Apceth Biopharma, Arbele Limited, Arcellx Inc, Atara Biotherapeutics, Atossa Therapeutics, Atreca/Xenor, Aurora Biopharma, Autolus Limited, Beam Therapeutics, Beijing Biohealthcare Biotechnology, Beijing Biohealthcare Biotechnology, Beijing Doing Biomedical, Beijing Immunochina Medical Science and Technology, Beijing Mario Biotech, Bellicum Pharmaceuticals, Benitec Biopharma Limited, Bioatla, Bioceltech Therapeutics, BioNTech, Biosceptre, Bluebird Bio, BrightPath Therapeutics, Bristol-Myers Squibb, Caribou Biosciences, Carina Biotech, CARsgen, Carsgen Therapeutics, Cartesian Therapeutics, Cartherics, CASI Pharmaceuticals/Juventas Cell Therapy, Celgene, Cellectis, Cellular Biomedicine Group, Celyad Oncology SA, Chimeric Therapeutics, Chongqing Precision Biotechnology Co., Ltd., Cogent Biosciences, Creative Biolabs, CRISPR Therapeutics, Curocell, Elpis Biopharmaceuticals, Endocyte, Enlivex Therapeutics Ltd, Eureka Therapeutics, Eutilex/Utilities, Exuma, FastBack Bio, Fate Therapeutics, Formula Pharmaceuticals, Fujifilm Holdings Corporation, Fundamenta Therapeutics, GC Cell, Genus oncology, Gilead Sciences, GlaxoSmithKline, Glycotype, Gracell Biotechnology, Grand Vista Biotechnology, Guangdong Zhaotai InVivo Biomedicine Co. Ltd., Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology Inc., Ltd., Helix BioPharma, Helocyte, Hemalogix, Henan Hualong Biotechnology, HRAIN Biotechnology, Humorigin, Hunan Zhaotai Yongren Medical Innovation, iCarTAB BioMed, iCell Gene Therapeutics, Immune Therapeutics, Immuneel, Immunicum, IN8Bio, InnoBation, Innovative Cellular Therapeutics, Innovent Biologics, Intellia Therapeutics, Janssen Pharmaceuticals, JW Therapeutics, KAEDI, Kecellitics Biotech Company Ltd, Kiromic BioPharma, Kite Pharma, Kuur Therapeutics, Liminatus Pharma, Luminary Therapeutics, Maxcyte, Medisix Therapeutics, Miltenyi Biotec, Minerva Biotechnologies, MolMed, Mustang Bio, Nanjing KAEDI Biotech, Noile-Immune Biotech, Novartis Pharmaceuticals, Obsidian Therapeutics, Oncternal Therapeutics, Orgenesis, Oxford Biomedica, Pepromene bio, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Poseida Therapeutics, Precigen, Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Protheragen, PTX Therapeutics, REGENERON, Sana Biotechnology, Sangamo, Senlang Bio, Sensei Biotherapeutics, Servier, Shanghai Biomed-union Biotechnology, Shanghai GeneChem Co., Ltd., Shanghai Longyao Biotechnology, Shanghai Unicar-Therapy Bio-medicine Technology, Shenzhen BinDeBio, Sinobioway Cell Therapy Co., Ltd., Sorrento Therapeutics, SymVivo, Synthekine, Takeda / Noile-Immune Biotech, Targazyme, TC BioPharm, Tessa Therapeutics Ltd., The Beijing Pregene Science and Technology Company, Tianjin Mycure Medical Technology, TILT Biotherapeutics, Timmune Biotech, Tmunity Therapeutics, ToolGen, TrakCel, Transgene, UWELL Biopharma, VCANBIO Cell & Gene Engineering Corporation, Ltd, VorBio, Wellington Zhaotai Therapies, WindMIL Therapeutics, Wugen, Wuhan Bio-Raid Biotechnology, Wuhan Sian Medical Technology, Xi’An Yufan Biotechnology, Xyphos Biosciences, Yake Biotechnology, Ziopharm Oncology Inc. Intrexon, and many others.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Emerging and Marketed Drugs Covered in the Report Include:

  • CD19-targeted CAR-T cells: Sinobioway Cell Therapy

  • CEA CAR T: Sorrento Therapeutics

  • CT 103A: Innovent Biologics

  • CTL119: Novartis

  • Descartes-11: Cartesian Therapeutics

  • EPCAM-targeted CAR T-cells: Sinobioway Cell Therapy

  • JWCAR029: JW Therapeutics

  • MB-CART2019.1: Miltenyi Biomedicine

  • TT11: Tessa Therapeutics

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/cart-cell-therapy-competitive-landscape

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. CAR T-cell Therapy Current Treatment Patterns

4. CAR T-cell Therapy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. CAR T-cell Therapy Late Stage Products (Phase-III)

7. CAR T-cell Therapy Mid-Stage Products (Phase-II)

8. CAR T-cell Therapy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. CAR T-cell Therapy Discontinued Products

13. CAR T-cell Therapy Product Profiles

14. Key Companies in the CAR T-cell Therapy Market

15. Key Products in the CAR T-cell Therapy Therapeutics Segment

16. Dormant and Discontinued Products

17. CAR T-cell Therapy Unmet Needs

18. CAR T-cell Therapy Future Perspectives

19. CAR T-cell Therapy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/cart-cell-therapy-competitive-landscape

 

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Insights, 2023 Updates | Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

Bob Gonzalez’s “A Flicker in the Water” is selected for Mariel Hemingway’s Book Club

A thrilling collection of tales from the high seas, “A Flicker in the Water: Inside the Tales” by Bob Gonzalez has been selected for Mariel Hemingway’s Book Club, a curated collection of excellent fiction and nonfiction that spans styles and genres. This most recent addition, “A Flicker in the Water” brings readers aboard a fishing vessel in the Gulf of Mexico, the Twister, for adventure-filled stories of chasing the ocean’s biggest catches.

With an engaging mix of humor and drama, the author shows the heroism, skill, and sometimes dangerous challenges faced by ocean fishermen, while also educating readers about marine life and the sea itself.

Mariel Hemingway, Oscar nominated actress, bestselling author, and granddaughter of the legendary Ernest Hemingway, says, “Bravo to Bob Gonzalez for this poignant window into the world of deep sea and the extraordinary fish that call it home. A Flicker in the Water is a telling title to the stories that emerge from that flicker. I tip my hat to Bob Gonzalez, to my dad and my grandfather who also see/saw the flickers of the water as a symbol of the men they wanted to be, men who spoke the language of the water.”

Providing a fascinating window into the lifestyle aboard a top fishing vessel, including major setbacks and massive successes, Gonzalez shares incredible stories that bring readers right into the action. Chasing blue marlin, swordfish, grouper, and beyond isn’t for the faint of heart, and these tales show just what it takes to reel them in!

“A Flicker in the Water” is available through retailers worldwide, including Amazon and Barnes and Noble. Learn more at https://mindstirmedia.com/mariel-hemingway-book-club/

About the author:

Bob grew up in North Eastern Pennsylvania near the Pocono mountains. After moving to Florida he pursued his love of deep sea fishing which led to the creation of his 2nd book “A FLICKER IN THE WATER” (Inside the Tales). The book is reminiscent of The Old Man and the Sea. After coming close in 2020 making it to the 6th game of the World Series Bob hopes to someday soon see the Tampa Bay Rays win their 1st World Series championship.

Media Contact
Company Name: MindStir Media LLC
Contact Person: Jen McNabney
Email: Send Email
Phone: 800-767-0531
Address:1 New Hampshire Ave Suite 125
City: Portsmouth
State: NH
Country: United States
Website: https://mindstirmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bob Gonzalez’s \”A Flicker in the Water\” is selected for Mariel Hemingway’s Book Club

Non-Alcoholic Steatohepatitis (NASH) Marketed and Emerging Pipeline Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

“Delveinsight Business Research LLP”
As per DelveInsight’s assessment, globally, about 100+ key pharma and biotech companies are working on 150+ pipeline drugs in the Non-Alcoholic Steatohepatitis (NASH) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Non-Alcoholic Steatohepatitis Market. 

The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Nonalcoholic Steatohepatitis (NASH) Pipeline Analysis

Non-Alcoholic Steatohepatitis (NASH) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Non-Alcoholic Steatohepatitis and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Non-Alcoholic Steatohepatitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 

Route of Administration

Non-Alcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Ongoing Clinical & Commercial Activities will Affect the Non-Alcoholic Steatohepatitis Therapeutic Segment @

https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

Non-Alcoholic Steatohepatitis (NASH) Therapeutics Assessment

There are approx. 130+ key companies developing therapies for Non-Alcoholic Steatohepatitis. Currently, Madrigal Pharmaceuticals is leading the therapeutics market with its Non-Alcoholic Steatohepatitis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market Include:

Akero Therapeutics, Albireo Pharma, Altimmune, Inc., Amgen, ARTham Therapeutics, Ascletis, AstraZeneca, Bird Rock Bio, Boston Pharmaceuticals, Bristol-Myers Squibb, Cascade Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cirius Therapeutics, DURECT Corporation, Enanta Pharmaceuticals, Enzychem Lifesciences, Galecto Biotech, Gmax Biopharm, GSK plc., Guangdong Zhongsheng Pharmaceutical, Hepion Pharmaceuticals, Ildong Pharmaceutical, Ildong Pharmaceutical, InorbitTX, Ionis Pharmaceuticals, J2H Biotech, LG Chem Life sciences, Liminal BioSciences, Madrigal Pharmaceuticals, Melior Pharmaceuticals, Merck Sharp & Dohme LLC, NorthSea Therapeutics, Palobiofarma, Pharmaxis, Pliant Therapeutics, Rivus Pharmaceuticals, Sciwind Biosciences, SCOHIA PHARMA, TaiwanJ Pharmaceuticals, Thoth Science, Tiziana Life Sciences, TransThera Biosciences, Viking Therapeutics, and many others.

Non-Alcoholic Steatohepatitis Emerging and Marketed Drugs Covered in the Report Include:

  • Resmetirom: Madrigal Pharmaceuticals

  • MSDC-0602K: Cirius Therapeutics

  • ION224: Ionis Pharmaceuticals

  • HU 6: Rivus Pharmaceuticals

  • HTD 1801: HighTide Biopharma

  • EDP-305: Enanta Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Non-Alcoholic Steatohepatitis Current Treatment Patterns

4. Non-Alcoholic Steatohepatitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Non-Alcoholic Steatohepatitis Late Stage Products (Phase-III)

7. Non-Alcoholic Steatohepatitis Mid-Stage Products (Phase-II)

8. Non-Alcoholic Steatohepatitis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Alcoholic Steatohepatitis Discontinued Products

13. Non-Alcoholic Steatohepatitis Product Profiles

14. Key Companies in the Non-Alcoholic Steatohepatitis Market

15. Key Products in the Non-Alcoholic Steatohepatitis Therapeutics Segment

16. Dormant and Discontinued Products

17. Non-Alcoholic Steatohepatitis Unmet Needs

18. Non-Alcoholic Steatohepatitis Future Perspectives

19. Non-Alcoholic Steatohepatitis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

 

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services and Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Alcoholic Steatohepatitis (NASH) Marketed and Emerging Pipeline Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Sickle Cell Disease Marketed and Emerging Pipeline Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

“Delveinsight Business Research LLP”
As per DelveInsight’s assessment, about 40+ key pharma and biotech companies are working on 50+ drugs in the Sickle Cell Disease therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Sickle Cell Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Sickle Cell Disease Market. 

The Sickle Cell Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Sickle Cell Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Sickle Cell Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Sickle Cell Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 

Route of Administration

Sickle Cell Disease (SCD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intranasal

  • Intrathecal

  • Intravenous

  • Oral

  • Oral/Intravenous

  • Parenteral

  • Subcutaneous

  • Subcutaneous/Intramuscular

  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Antisense oligonucleotide

  • Gene therapy

  • Hormones

  • Neuropeptides

  • Oligonucleotides

  • Small Molecule

  • Triglyceride

Learn How the Ongoing Clinical & Commercial Activities will Affect the Sickle Cell Disease Therapeutic Segment @

https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight

Sickle Cell Disease Therapeutics Landscape

There are approx. 40+ key companies developing therapies for Sickle Cell Disease (SCD). Currently,  Vertex Pharmaceuticals is leading the therapeutics market with its Sickle Cell Disease (SCD) drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Sickle Cell Disease (SCD) Therapeutics Market Include:

Agios Pharmaceuticals, Alfasigma, Aruvant Sciences, bluebird bio, Cellectis, CSL Behring, Editas Medicine, ExCellThera, Forma therapeutics, Gamida Cell, Global Blood Therapeutics, Inc., Graphite Bio, KM Biologics, Novartis, Novo Nordisk, Pfizer, Sana Biotechnology, Takeda, Vertex Pharmaceuticals, and many more.

Sickle Cell Disease (SCD) Emerging and Marketed Drugs Covered in the Report Include:

  • BPX-501 T cells: Bellicum Pharmaceuticals

  • Canakinumab: Novartis

  • EPI01: Novo Nordisk

  • CTX001: Vertex Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Sickle Cell Disease Current Treatment Patterns

4. Sickle Cell Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Sickle Cell Disease Late Stage Products (Phase-III)

7. Sickle Cell Disease Mid-Stage Products (Phase-II)

8. Sickle Cell Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Sickle Cell Disease Discontinued Products

13. Sickle Cell Disease Product Profiles

14. Key Companies in the Sickle Cell Disease Market

15. Key Products in the Sickle Cell Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Sickle Cell Disease Unmet Needs

18. Sickle Cell Disease Future Perspectives

19. Sickle Cell Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight

 

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Strategies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sickle Cell Disease Marketed and Emerging Pipeline Drugs Assessment | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Age-related Macular Degeneration (AMD) Pipeline Drugs Assessment, 2023 | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

“Delveinsight Business Research LLP”
As per DelveInsight, the Age-related Macular Degeneration (AMD) therapeutics market is anticipated to evolve immensely in the coming years owing to the expected launch of therapies and the increasing prevalence of AMD. Companies across the globe are diligently working toward the development of novel treatment therapies, with a considerable amount of success over the years.

At present, pharmaceutical companies such as Apellis Pharmaceuticals (Pegcetacoplan), Iveric bio (Zimura), Genentech (Roche; RO7171009; RG6147), Ionis Pharmaceuticals/ Roche (IONIS-FB-LRx), Allegro Ophthalmics (Luminate), NGM Biopharmaceuticals (NGM621), Stealth BioTherapeutics (Elamipretide), Regenerative Patch Technologies (CPCB-RPE1), CellCure Neurosciences/Lineage Cell Therapeutics/ Roche (OpRegen), Gyroscope Therapeutics (GT005), and others, are working on developing a novel approach to treat Age-related Macular Degeneration (AMD).

The emerging therapies are based on different types of mechanisms of action, including C3 inhibitors, C5 inhibitors, Integrin Inhibitors, Anti-C1q antibody, Anti-C3 antibody, Factor D inhibitors, HtrA1, ASO Complement Factor B, and others.

“Age-related Macular Degeneration (AMD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Age-related Macular Degeneration Market. 

The Age-related Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Age-related Macular Degeneration (AMD) Pipeline Analysis

Age-related Macular Degeneration (AMD) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Age-related Macular Degeneration and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Age-related Macular Degeneration market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Age-related Macular Degeneration Therapeutic Segment @

https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight

The Leading Companies in the Age-related Macular Degeneration (AMD) Therapeutics Market Include:

Alexion Pharmaceuticals, Alkahest Inc, Alkeus Pharmaceuticals, Allegro Ophthalmics, Annexon Biosciences, Apellis Pharmaceuticals, AstraZeneca, CellCure Neurosciences, Clearside Biomedical, Evergreen Therapeutics, Gemini Therapeutics, Graybug Vision, Gyroscope Therapeutics and Novartis, Ionis Pharmaceuticals, Iveric Bio, Kodiak Sciences Inc., Luxa Biotechnology, NGM Biopharmaceuticals, Novartis, Opthea Limited, Outlook Therapeutics, Inc., PanOptica, Inc., Regenerative Patch Technologies, Regeneron Pharmaceuticals, REGENXBIO, Ribomic USA Inc, Roche, Stealth BioTherapeutics, Unity Biotechnology, Inc, and many more.

Age-related Macular Degeneration Marketed and Emerging Drugs Covered in the Report Include:

  • Beovu (brolucizumab): Novartis

  • Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca

  • EG-301: Evergreen Therapeutics

  • Eylea (aflibercept): Regeneron Pharmaceuticals

  • KSI-301: Kodiak Sciences Inc.

  • Lucentis (ranibizumab): Roche

  • OPT-302: Opthea Limited

  • RGX-314: Regenxbio

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight 

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Age-related Macular Degeneration Current Treatment Patterns

4. Age-related Macular Degeneration – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Age-related Macular Degeneration Late Stage Products (Phase-III)

7. Age-related Macular Degeneration Mid-Stage Products (Phase-II)

8. Age-related Macular Degeneration Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Age-related Macular Degeneration Discontinued Products

13. Age-related Macular Degeneration Product Profiles

14. Key Companies in the Age-related Macular Degeneration Market

15. Key Products in the Age-related Macular Degeneration Therapeutics Segment

16. Dormant and Discontinued Products

17. Age-related Macular Degeneration Unmet Needs

18. Age-related Macular Degeneration Future Perspectives

19. Age-related Macular Degeneration Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight

 

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Strategies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Age-related Macular Degeneration (AMD) Pipeline Drugs Assessment, 2023 | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies